Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience Announces Research Collaboration with the NRCMM

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
New collaboration aims to develop disease-specific experimental models for translational medical research.

Crown Bioscience, Inc. has announced that an agreement has been reached with the National Resource Center for Mutant Mice (NRCMM), in Nanjing, Jiangsu Province, China.

The strategic partnership will focus on developing new experimental cancer models to advance translational medical research and the treatment of cancers.

The immediate focus of the research collaboration will be to build new experimental models for cancer research leveraging the proprietary technologies of both companies.

The collaboration is expected to significantly expand the research capabilities of both organizations in translational oncology and will thus benefit the global research community fighting cancers.

Crown Bioscience is the premier service provider of translational oncology and metabolic diseases platforms providing focused disease models. It has one of the largest and most advanced translational oncology platforms featuring fully annotated collections of proprietary patient derived xenograft (PDX) models (>1000).

NRCMM is a leading research organization specialized in genetically engineered mutant mouse (GEMM), with vast resources, including a large collection of GEMMs, many of which mimic human cancers. Both parties have complimentary expertise and experience in Oncology and GEMMs, and therefore the established joint effort will have great synergy in creating new translational oncology platforms based on GEMMs.

The collaboration will offer significantly expanded new mouse cancer and leukemia models based on GEMM as well as new human xenografts, in addition to the current PDX and CDX platforms (Cell line Derived Xenograft) at Crown and the current GEMMs at NRCMM.

In particular, novel mouse strains with various humanizations could be particularly powerful tools for immune-oncology research and immunotherapy drug evaluations.

After the signing of the agreement, Dr. Jean-Pierre Wery, Crown’s President, commented: “Crown plays a leading role in providing cutting-edge translational platforms and cost effective drug development solutions for almost all top pharmaceutical companies worldwide. Crown is very happy to partner with NRCMM, the leading research institute for genetically engineered animals in China. This partnership will offer world-class translational oncology services, and ultimately benefit cancer patients around the world. This collaboration will further strengthen Crown’s leading position as the oncology translational medicine partner for drug discovery organizations worldwide”.

Dr. Gao, Director of NRCMM, also commented: “As the largest government-funded research institute focusing on genetically engineered mice in China, NRCMM is an important member of the global community of GEMM research. Working together with a world leading translational oncology service provider, such as Crown, the combined expertise of Crown in oncology and our GEMM can certainly offer great GEMM-based oncology platforms to our partners in China and around the world. We are certainly excited about this opportunity.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!